SRPT – Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.SRPT
$36.20Name : Sarepta Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $3,557,627,392.00
EPSttm : -2.64
Sarepta Therapeutics, Inc.
$36.20
0.47%$0.17Float Short %
7.26
Margin Of Safety %
Put/Call OI Ratio
0.59
EPS Next Q Diff
5.79
EPS Last/This Y
-2.29
EPS This/Next Y
8.43
Price
36.2
Target Price
102.48
Analyst Recom
1.44
Performance Q
-66.99
Relative Volume
1.9
Beta
0.64
Ticker: SRPT
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | SRPT | 54.59 | 0.64 | 0.45 | 58702 |
| 2025-04-15 | SRPT | 54.39 | 0.59 | 0.47 | 60089 |
| 2025-04-16 | SRPT | 53.93 | 0.58 | 0.52 | 60475 |
| 2025-04-17 | SRPT | 53.8 | 0.57 | 30.18 | 61258 |
| 2025-04-18 | SRPT | 53.79 | 0.57 | 36.36 | 61258 |
| 2025-04-21 | SRPT | 55.24 | 0.93 | 1.58 | 61342 |
| 2025-04-22 | SRPT | 59.3 | 0.97 | 0.56 | 64870 |
| 2025-04-23 | SRPT | 59.5 | 0.95 | 0.51 | 69068 |
| 2025-04-24 | SRPT | 61.81 | 0.92 | 0.16 | 71174 |
| 2025-04-25 | SRPT | 60.44 | 0.90777792500331 | 0.69982847341338 | 71990 |
| 2025-04-28 | SRPT | 61.51 | 0.97676341449507 | 0.21689895470383 | 69333 |
| 2025-04-29 | SRPT | 60.89 | 0.97 | 4.56 | 70175 |
| 2025-04-30 | SRPT | 62.42 | 1.01 | 0.17 | 72737 |
| 2025-05-01 | SRPT | 62.81 | 1.00 | 0.34 | 73259 |
| 2025-05-02 | SRPT | 63.55 | 0.99 | 0.20 | 74517 |
| 2025-05-05 | SRPT | 63.99 | 1.00 | 1.05 | 72946 |
| 2025-05-06 | SRPT | 46.8 | 0.96 | 1.21 | 77401 |
| 2025-05-07 | SRPT | 36.51 | 0.96 | 0.48 | 90716 |
| 2025-05-08 | SRPT | 36.53 | 0.80 | 0.47 | 102993 |
| 2025-05-09 | SRPT | 36.28 | 0.71 | 0.15 | 111031 |
| 2025-05-12 | SRPT | 36.36 | 0.60 | 0.53 | 113470 |
| 2025-05-13 | SRPT | 36.17 | 0.59 | 0.57 | 116043 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | SRPT | 54.63 | -78.6 | 1391.2 | 8.00 |
| 2025-04-15 | SRPT | 54.42 | -129.9 | 1274.8 | 8.00 |
| 2025-04-16 | SRPT | 53.91 | -129.9 | 1266.2 | 8.00 |
| 2025-04-17 | SRPT | 53.79 | -129.9 | 1276.4 | 8.00 |
| 2025-04-18 | SRPT | 53.79 | -129.9 | 1280.9 | 8.00 |
| 2025-04-21 | SRPT | 55.22 | -129.9 | 1322.5 | 8.00 |
| 2025-04-22 | SRPT | 59.31 | -159.1 | 1396.5 | 8.00 |
| 2025-04-23 | SRPT | 59.49 | -152.2 | 1285.5 | 8.00 |
| 2025-04-24 | SRPT | 61.76 | -189.0 | 1340.5 | 8.00 |
| 2025-04-25 | SRPT | 60.44 | -189.0 | 1247.4 | 7.60 |
| 2025-04-28 | SRPT | 61.51 | -189.0 | 1308.5 | 7.60 |
| 2025-04-29 | SRPT | 60.85 | -189.0 | 1264.0 | 7.60 |
| 2025-04-30 | SRPT | 62.40 | -189.0 | 1320.6 | 7.60 |
| 2025-05-01 | SRPT | 62.78 | -189.0 | 1290.5 | 7.60 |
| 2025-05-02 | SRPT | 63.51 | -189.0 | 1299.0 | 7.60 |
| 2025-05-05 | SRPT | 63.66 | -189.0 | 1284.6 | 7.60 |
| 2025-05-06 | SRPT | 46.60 | -189.0 | 862.1 | 7.60 |
| 2025-05-07 | SRPT | 36.72 | -189.0 | 945.4 | 7.60 |
| 2025-05-08 | SRPT | 36.53 | 493.2 | 1698.1 | 7.60 |
| 2025-05-09 | SRPT | 36.28 | 254.2 | 1696.7 | 0.40 |
| 2025-05-12 | SRPT | 36.37 | 254.2 | 1708.6 | 0.40 |
| 2025-05-13 | SRPT | 36.20 | 254.2 | 249.8 | 0.05 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | SRPT | -0.25 | 3.25 | 6.69 |
| 2025-04-15 | SRPT | -0.25 | 3.25 | 6.69 |
| 2025-04-16 | SRPT | -0.25 | 3.25 | 6.69 |
| 2025-04-17 | SRPT | -0.25 | 3.25 | 6.69 |
| 2025-04-18 | SRPT | -0.25 | 3.25 | 6.69 |
| 2025-04-21 | SRPT | -0.25 | 4.20 | 6.69 |
| 2025-04-22 | SRPT | -0.25 | 4.20 | 6.69 |
| 2025-04-23 | SRPT | -0.25 | 4.20 | 6.69 |
| 2025-04-24 | SRPT | -0.25 | 4.20 | 6.69 |
| 2025-04-25 | SRPT | -0.25 | 4.20 | 6.69 |
| 2025-04-28 | SRPT | -0.25 | 4.19 | 7.27 |
| 2025-04-29 | SRPT | -0.25 | 4.19 | 7.27 |
| 2025-04-30 | SRPT | -0.24 | 4.19 | 7.27 |
| 2025-05-01 | SRPT | -0.24 | 4.19 | 7.18 |
| 2025-05-02 | SRPT | -0.24 | 4.19 | 7.18 |
| 2025-05-05 | SRPT | -0.24 | 3.65 | 7.18 |
| 2025-05-06 | SRPT | -0.24 | 3.65 | 7.18 |
| 2025-05-07 | SRPT | -0.24 | 3.65 | 7.18 |
| 2025-05-08 | SRPT | -0.24 | 3.65 | 7.18 |
| 2025-05-09 | SRPT | -0.24 | 3.65 | 7.18 |
| 2025-05-12 | SRPT | -0.24 | 0.21 | 7.26 |
| 2025-05-13 | SRPT | -0.24 | 0.21 | 7.26 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-4.6
Avg. EPS Est. Current Quarter
1.35
Avg. EPS Est. Next Quarter
1.19
Insider Transactions
-0.24
Institutional Transactions
0.21
Beta
0.64
Average Sales Estimate Current Quarter
562
Average Sales Estimate Next Quarter
618
Fair Value
Quality Score
47
Growth Score
56
Sentiment Score
1
Actual DrawDown %
80.1
Max Drawdown 5-Year %
-79.7
Target Price
102.48
P/E
Forward P/E
4.86
PEG
P/S
1.59
P/B
3.11
P/Free Cash Flow
EPS
-2.58
Average EPS Est. Cur. Y
0.05
EPS Next Y. (Est.)
8.48
Target Price Estimates Raised
Target Price Estimates Lowered
3
Profit Margin
-11.12
Relative Volume
1.9
Return on Equity vs Sector %
-45.4
Return on Equity vs Industry %
-28.5
EPS 1 7Days Diff
-7.6
EPS 1 30Days Diff
-9.03
EBIT Estimation
249.8
Sarepta Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 1372
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
stock quote shares SRPT – Sarepta Therapeutics, Inc. Stock Price stock today
news today SRPT – Sarepta Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SRPT – Sarepta Therapeutics, Inc. yahoo finance google finance
stock history SRPT – Sarepta Therapeutics, Inc. invest stock market
stock prices SRPT premarket after hours
ticker SRPT fair value insiders trading